Nuformix PLC - London-based pharmaceutical firm targeting fibrosis and oncology - Says NXP002, a potential treatment for idiopathic pulmonary fibrosis, has successfully completed pre-clinical tolerability studies. "Tolerability has been demonstrated across a new range of doses, including higher doses than previously given," it explains. Work now commences to explore how the new doses studied can best optimise efficacy and the treatment's positive pharmacological profile.
Current stock price: 0.62 pence, up 8.5% in London on Wednesday
12-month change: down 60%
By Heather Rydings; heatherrydings@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Nuformix (NFX)